A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
Kebenko, Maxim, Goebeler, Marie-Elisabeth, Wolf, Martin, Hasenburg, Annette, Seggewiss-Bernhardt, Ruth, Ritter, Barbara, Rautenberg, Beate, Atanackovic, Djordje, Kratzer, Andrea, Rottman, James B., Friedrich, Matthias, Vieser, Eva, Elm, Stefanie, Patzak, Ingrid, Wessiepe, Dorothea, Stienen, Sabine, Fiedler, Walter
Published in Oncoimmunology (01.01.2018)
Published in Oncoimmunology (01.01.2018)
Get full text
Journal Article
A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors
Fiedler, Walter M., Wolf, Martin, Kebenko, Maxim, Goebeler, Marie-Elisabeth, Ritter, Barbara, Quaas, Alexander, Vieser, Eva, Hijazi, Youssef, Patzak, Ingrid, Friedrich, Matthias, Kufer, Peter, Frankel, Stanley, Seggewiss-Bernhardt, Ruth, Kaubitzsch, Sabine
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article